RODOLFO IPPOLITI

Has grant

FULL PROFESSOR OF MOLECULAR BIOLOGY

University of L'Aquila
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rodolfo Ippoliti is a Full Professor of Molecular Biology at Università degli Studi dell'Aquila, Italy. His research focuses on molecular mechanisms in cancer therapy, including antibody-drug conjugates and bio-tailored sensing at the nanoscale. Recent articles highlight his work on therapeutic targets in glioblastoma and the implications of environmental toxins on developmental biology.

Recent Grants

Grant: Close

Produzione di proteine ricombinanti in Pichia pastoris

Open Date: 2019-06-01

Close Date: 2020-06-01

Grant: Close

Generazione di un innovativo anticorpo-farmaco non internalizzante

Open Date: 2018-10-01

Close Date: 2020-02-01

Grant: Close

PRODUZIONE E CARATTERIZZAZIONE DI UN KIT DIAGNOSTICO PER IL CANCRO DEL CAVO ORALE

Open Date: 2018-03-01

Close Date: 2018-12-01

Grant: Close

Caratterizzazione di un coniugato tra l'anticorpo 1959 ed il farmaco DM1

Open Date: 2016-06-01

Close Date: 2016-12-01

Grant: Close

TEST DI FUNZIONAMENTO IN VITRO ED IN VIVO DEL SISTEMA DI RILASCIO IN SITU DI UN CONIUGATO TRA L'ANTICORPO MONOCLONALE 1959 ED IL FARMACO DM1.

Open Date: 2015-06-01

Close Date: 2015-12-01

Articles (19)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Affibodies and designed ankyrin repeat proteins (DARPins) are synthetic proteins originally derived from the Staphylococcus aureus virulence factor protein A and the human ankyrin repeat proteins, respectively. The use of these molecules in healthcare has been recently proposed as they are endowed with biochemical and biophysical features heavily demanded to target and fight diseases, as they have a strong binding affinity, solubility, small size, multiple functionalization sites, biocompatibility, and are easy to produce; furthermore, impressive chemical and thermal stability can be achieved. especially when using affibodies. In this sense, several examples reporting on affibodies and DARPins conjugated to nanomaterials have been published, demonstrating their suitability and feasibility in nanomedicine for cancer therapy. This minireview provides a survey of the most recent studies describing affibody- and DARPin-conjugated zero-dimensional nanomaterials, including inorganic, organic, and biological nanoparticles, nanorods, quantum dots, liposomes, and protein- and DNA-based assemblies for targeted cancer therapy in vitro and in vivo.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (15)

Elisabetta Benedetti

University of L'Aquila

ITALY
View details

Rita RONCONE

Professore Ordinario di Psichiatria

University of L'Aquila

ITALY
View details

Miryam Perrucci

University of Teramo

ITALY
View details

Radosveta Gencheva

Karolinska Institutet

SWEDEN
View details

Francesco ANGELUCCI

Full Professor of Biochemistry

University of L'Aquila

ITALY
View details

Mariano Catanesi

University of L'Aquila

ITALY
View details

Matteo Ardini

-

ITALY
View details

Nicoletta ZOPPI

Professor

University of Brescia

ITALY
View details

Francesco Giansanti

Associate Professor

University of L'Aquila

ITALY
View details

Ruggero De Paulis

Saint Camillus International University of Health Sciences

ITALY
View details

Marcello Locatelli

Associate professor in ANALYTICAL CHEMISTRY

University “G. d’Annunzio” of Chieti-Pescara

ITALY
View details

Francesco Brancati

Professor

University of L'Aquila

ITALY
View details

Gianluca Sala

Associate Professor

University of Chieti-Pescara

ITALY
View details

Samantha Delaney

Faculty of Health and Medical Sciences, University of Copenhagen

DENMARK
View details

Outi Keinänen

The University of Alabama

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.